© 2019 All rights Reserved.
“I like that this is not off the shelf. I explain that this is a treatment that uses the patient’s own tumor cells and that is exciting to patients – the idea of medically Immunizing them against their own tumor.”
Ray Merrill’s story
Cancer is one of the deadliest diseases that arises from our own cells. This creates a very confusing situation for our immune system. To launch an immune response, the body has to be able to tell the difference between cells that are “self” and “non-self.” One reason cancer is so difficult to treat is that it avoids detection because the immune system thinks it is “self.” Without a way for the immune system to tell the difference between a healthy cell and a cancer cell, there is little the body can do to prevent cancer from taking over.
Orbis’ technology uses a proprietary particle delivery system that helps the body’s immune system recognize foreign invaders as “non-self” allowing it to seek out and to destroy cancer and other immune-mediated conditions. Orbis has developed a pipeline of immunotherapy-based products that are designed to harness the potent role of the body’s innate immune system to repair and to restore health.
Each of our product candidates have their own distinct clinical characteristics, target indications, commercialization potential, and partnering opportunities.
At Orbis, we are developing transformative medicines that have the potential improve the lives of people with immune-mediated conditions. We know that to bring the most innovative, effective and safe treatment options to patients, we need to go beyond our walls. To that end, we are actively seeking partners and licensing opportunities in the U.S. and around the world to explore the therapeutic potential of our personalized therapeutic cancer vaccines.
For investment information and investment opportunities in Orbis or one of its subsidiaries,
please contact Riley Polk at firstname.lastname@example.org.
111 Smith Hines Road Suite E, Greenville, South Carolina 29607, United States.